Mechanisms of resistance to EGFR targeted therapies

被引：59

作者：

Hrustanovic, Gorjan ^{[1
]}

Lee, Bianca J. ^{[1
]}

Bivona, Trever G. ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA

来源：

CANCER BIOLOGY & THERAPY | 2013年 / 14卷 / 04期

关键词：

EGFR; EGFR TKI; lung cancer; targeted therapy; resistance; erlotinib; kinase; GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; PAN-ERBB INHIBITOR; K-RAS MUTATIONS; ACQUIRED-RESISTANCE; KINASE INHIBITORS; COLORECTAL-CANCER; MET AMPLIFICATION; GENE-MUTATIONS; T790M MUTATION;

D O I：

10.4161/cbt.23627

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EGFR is a validated therapeutic target in many human cancers. EGFR targeted therapies are in widespread clinical use in patients with non-small cell lung cancer and other tumor types. Despite the clinical success of EGFR targeted therapy, resistance to treatment is a significant barrier to the optimized use of EGFR inhibitors to cure patients with lung and other cancers. Here, we review established and emerging mechanisms of resistance to EGFR targeted therapy and highlight strategies that could overcome treatment resistance and therefore enhance clinical outcomes.

引用

页码：304 / 314

页数：11

共 137 条

[1] Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung [J].

Alam, Naheed ;

Gustafson, Karen S. ;

Ladanyi, Marc ;

Zakowski, Maureen F. ;

Kapoor, Atul ;

Truskinovsky, Alexander M. ;

Dudek, Arkadiusz Z. .

CLINICAL LUNG CANCER, 2010, 11 (05) :E1-E4

[2]

[Anonymous], PATHOLOG RES INT

[3] Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay [J].

Arcila, Maria E. ;

Oxnard, Geoffrey R. ;

Nafa, Khedoudja ;

Riely, Gregory J. ;

Solomon, Stephen B. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Pao, William ;

Miller, Vincent A. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1169-1180

[4] EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis [J].

Ardito, Christine M. ;

Gruener, Barbara M. ;

Takeuchi, Kenneth K. ;

Lubeseder-Martellato, Clara ;

Teichmann, Nicole ;

Mazur, Pawel K. ;

DelGiorno, Kathleen E. ;

Carpenter, Eileen S. ;

Halbrook, Christopher J. ;

Hall, Jason C. ;

Pal, Debjani ;

Briel, Thomas ;

Herner, Alexander ;

Trajkovic-Arsic, Marija ;

Sipos, Bence ;

Liou, Geou-Yarh ;

Storz, Peter ;

Murray, Nicole R. ;

Threadgill, David W. ;

Sibilia, Maria ;

Washington, M. Kay ;

Wilson, Carole L. ;

Schmid, Roland M. ;

Raines, Elaine W. ;

Crawford, Howard C. ;

Siveke, Jens T. .

CANCER CELL, 2012, 22 (03) :304-317

[5] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[6] Somatic mutations of EGFR in colorectal cancers and glioblastomas [J].

Barber, TD ;

Vogelstein, B ;

Kinzler, KW ;

Velculescu, VE .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2883-2883

[7] Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers [J].

Barkovich, Krister J. ;

Hariono, Sujatmi ;

Garske, Adam L. ;

Zhang, Jie ;

Blair, Jimmy A. ;

Fan, Qi-Wen ;

Shokat, Kevan M. ;

Nicolaides, Theodore ;

Weiss, William A. .

CANCER DISCOVERY, 2012, 2 (05) :450-457

[8] Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma [J].

Bean, James ;

Riely, Gregory J. ;

Balak, Marissa ;

Marks, Jenifer L. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7519-7525

[9] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[10] Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC) [J].

Belani, C. P. ;

Goss, G. ;

Blumenschein, G., Jr. .

CANCER TREATMENT REVIEWS, 2012, 38 (03) :173-184

← 1 2 3 4 5 6 7 8 9 10 →